20 Rec'd P31/P10 21 MARODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

Complete if Known Substitute for form 1449B/PTO Not yet assigned // 個 **Application Number** INFORMATION DISCLOSURE April 16, 2006 Filing Date STATEMENT BY APPLICANT Robert HOFMEISTER **First Named Inventor** Date Submitted: April 16, 2006 Not yet assigned **Group Art Unit** Not yet assigned **Examiner Name** (use as many sheets as necessary) 028622-0148 Attorney Docket Number of Sheet

				Į	J.S. PATENT DOCUMENTS				
yaminar	Cite No.1	U.S. Patent Document			ne of Patentee or Applicant of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	•	
Examiner Initials*		Number	Kind Code <sup>2</sup> (if known)	Cited Document		MM-DD-YYYY	Figures Appear		
/AMG/	1	6,491,916	B1		Bluestone et al.	12-10-2002			
/AMĞ/	2	2004/0162411	A1		Lanzavecchia	08-19-2002			
				FC	REIGN PATENT DOCUME	NTS  Date of Publication of	Pages, Columns, Lines,	T :	
Examiner Initials*	Cite No.1	Foreign Patent Document Office <sup>3</sup> Number <sup>4</sup> Kind Code		ode	Name of Patentee or Applicant of Cited Documents	Cited Document	Where Relevant Passages or Relevant Figures Appear	T	
/AMG/	3	WO 02/0	066514	Á2	Merck Patent GmbH	08-29-2002		+-	
/AMG/_	4		20 276	A1	Celltech Limited	10-19-1994		+-	
/AMG/	5		/54440	A1	Bernd Dörken	10-28-1999			
71 1				NON	PATENT LITERATURE DOCU	MENTS		_	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
/AMG/	6	K. MALETZ, et al., "Bispecific Single-Chain Antibodies As Effective Tools For Eliminating Epithelial Cancer Cells From Human Stem Cell Preparations By Redirected Cell Cytotoxicity," Int. J. Cancer, Vol. 93, pages 409-416 (2001).							
								_	
								1	

Examiner	/Anna M. Cuccow/	Date Considered	01/22/2010
Signature	/Anne M. Gussow/		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). Standard ST.30 is indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if